Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

[1]  Yu Pan,et al.  Rab31 promotes metastasis and cisplatin resistance in stomach adenocarcinoma through Twist1-mediated EMT , 2023, Cell Death & Disease.

[2]  J. Christensen,et al.  Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer , 2022, Cancer discovery.

[3]  Wenwei Hu,et al.  Metabolic enzyme LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer , 2022, Nature metabolism.

[4]  A. Sasaki,et al.  Beyond Warburg: LDHA activates RAC for tumour growth. , 2022, Nature metabolism.

[5]  Zhengfan Jiang,et al.  Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity , 2022, Cell Research.

[6]  B. Neel,et al.  Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy , 2022, Cancer discovery.

[7]  A. Koide,et al.  Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Ferrer,et al.  Discovery of small molecule inhibitors that effectively disrupt IQGAP1-Cdc42 interaction in breast cancer cells , 2022, Scientific Reports.

[9]  T. Kang,et al.  A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers , 2022, Cell Research.

[10]  W. Gu,et al.  Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine , 2022, Nature Communications.

[11]  Heidi Ledford.  Cancer drugs are closing in on some of the deadliest mutations , 2022, Nature.

[12]  Ella T. Lifset,et al.  Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor , 2022, Nature Medicine.

[13]  The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis , 2022, Nature Medicine.

[14]  T. Yuan,et al.  Fluorescent Biosensor for Measuring Ras Activity in Living Cells. , 2022, Journal of the American Chemical Society.

[15]  K. Shokat,et al.  A covalent inhibitor of K-Ras(G12C) induces MHC-I presentation of haptenated peptide neoepitopes targetable by immunotherapy , 2022, Cancer cell.

[16]  Kwok-Kin Wong,et al.  The current state of the art and future trends in RAS-targeted cancer therapies , 2022, Nature Reviews Clinical Oncology.

[17]  K. Shokat,et al.  Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile , 2022, Journal of the American Chemical Society.

[18]  M. Kozlov,et al.  Generation of nanoscopic membrane curvature for membrane trafficking , 2022, Nature reviews. Molecular cell biology.

[19]  K. Shokat,et al.  Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S) , 2022, Nature Chemical Biology.

[20]  Lin Miao,et al.  Cdc42 promotes thyroid cancer cell proliferation and migration and tumor‐associated macrophage polarization through the PTEN/AKT pathway , 2022, Journal of biochemical and molecular toxicology.

[21]  C. Ungermann,et al.  Vesicle transport: Exocyst follows PIP2 to tether membranes , 2022, Current Biology.

[22]  Adagrasib Response Remains Strong in NSCLC. , 2022, Cancer discovery.

[23]  P. Jänne,et al.  Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. , 2022, The New England journal of medicine.

[24]  Fengqin Gao,et al.  KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy , 2022, Cell reports.

[25]  Joseph B. DeGrandchamp,et al.  A two-component protein condensate of the EGFR cytoplasmic tail and Grb2 regulates Ras activation by SOS at the membrane , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Der,et al.  RHOA takes the RHOad less traveled to cancer. , 2022, Trends in cancer.

[27]  F. Giorgini,et al.  Therapeutic Targeting of Rab GTPases: Relevance for Alzheimer’s Disease , 2022, Biomedicines.

[28]  Daniel S. Terry,et al.  GPCR-mediated β-arrestin activation deconvoluted with single-molecule precision , 2022, Cell.

[29]  Matthew J. Smith,et al.  Functional diversity in the RAS subfamily of small GTPases. , 2022, Biochemical Society transactions.

[30]  M. Ikura,et al.  Hitting the hotspots , 2022, Nature Chemical Biology.

[31]  P. Singh,et al.  The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates KRAS expression in pancreatic ductal adenocarcinoma cells , 2022, Nucleic acids research.

[32]  Gabriel Cornilescu,et al.  Insights into the Cross Talk between Effector and Allosteric Lobes of KRAS from Methyl Conformational Dynamics. , 2022, Journal of the American Chemical Society.

[33]  S. Barthorpe,et al.  Effective drug combinations in breast, colon and pancreatic cancer cells , 2022, Nature.

[34]  K. Shokat,et al.  Drugging the Next Undruggable KRAS Allele-Gly12Asp. , 2022, Journal of medicinal chemistry.

[35]  A. Bennett,et al.  An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies , 2022, Cardiovascular Drugs and Therapy.

[36]  Yaxue Zhao,et al.  Molecular dynamics simulations reveal the activation mechanism of mutations G12V and Q61L of Cdc42 , 2022, Proteins.

[37]  E. Miska,et al.  Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state , 2022, Molecular cell.

[38]  M. Ikura,et al.  Regulation of GTPase function by autophosphorylation. , 2022, Molecular cell.

[39]  M. Yohe,et al.  The RASopathies: from pathogenetics to therapeutics , 2022, Disease models & mechanisms.

[40]  G. Piazza,et al.  The path to the clinic: a comprehensive review on direct KRASG12C inhibitors , 2022, Journal of Experimental & Clinical Cancer Research.

[41]  G. Piazza,et al.  The path to the clinic: a comprehensive review on direct KRASG12C inhibitors , 2022, Journal of experimental & clinical cancer research : CR.

[42]  Melinda M. Mulvihill,et al.  Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors , 2022, Nature Biotechnology.

[43]  J. Parker,et al.  Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition , 2022, The Journal of clinical investigation.

[44]  Sarah Crunkhorn.  Screening ultra-large virtual libraries , 2022, Nature reviews. Drug discovery.

[45]  Chaoni Xiao,et al.  Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy. , 2022, Pharmacology & therapeutics.

[46]  J. Minna,et al.  Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer , 2021, Nature Communications.

[47]  C. Guignabert,et al.  Smooth muscle Rac1 contributes to pulmonary hypertension , 2019, British journal of pharmacology.

[48]  OUP accepted manuscript , 2022, Nucleic Acids Research.

[49]  OUP accepted manuscript , 2022, The Oncologist.

[50]  Ming Liu,et al.  Semi-Synthesis, Cytotoxic Evaluation, and Structure—Activity Relationships of Brefeldin A Derivatives with Antileukemia Activity , 2021, Marine drugs.

[51]  Yurii S. Moroz,et al.  Synthon-based ligand discovery in virtual libraries of over 11 billion compounds , 2021, Nature.

[52]  P. Wild,et al.  KRAS Mutations in Squamous Cell Carcinomas of the Lung , 2021, Frontiers in Oncology.

[53]  Hong Liang,et al.  Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer. , 2021, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Jiang Liu,et al.  FDA Approval Summary: Sotorasib for KRAS G12C Mutated Metastatic NSCLC. , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  J. Blake,et al.  Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor. , 2021, Journal of medicinal chemistry.

[56]  T. Luther,et al.  Rab31-dependent regulation of transforming growth factor ß expression in breast cancer cells , 2021, Molecular Medicine.

[57]  M. Berger,et al.  Diverse alterations associated with resistance to KRAS(G12C) inhibition , 2021, Nature.

[58]  J. Groves,et al.  Relating cellular signaling timescales to single-molecule kinetics: A first-passage time analysis of Ras activation by SOS , 2021, Proceedings of the National Academy of Sciences.

[59]  Hubing Shi,et al.  Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer , 2021, Oncogene.

[60]  Brandon Yushan Feng,et al.  Benchmarking AlphaFold for protein complex modeling reveals accuracy determinants , 2021, bioRxiv.

[61]  J. Downward,et al.  Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers , 2021, bioRxiv.

[62]  M. T. Beck,et al.  KRAS is vulnerable to reversible switch-II pocket engagement in cells , 2021, bioRxiv.

[63]  A. Ganesan,et al.  Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer , 2021, bioRxiv.

[64]  P. Lito,et al.  The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS , 2021, Science.

[65]  C. Der,et al.  Filling in the GAPs in understanding RAS , 2021, Science.

[66]  V. Sanz-Moreno,et al.  RhoGTPase Signalling in Cancer Progression and Dissemination. , 2021, Physiological reviews.

[67]  J. Hancock,et al.  Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity , 2021, Nature Communications.

[68]  Zongzhe Jiang,et al.  G-quadruplex DNA: a novel target for drug design , 2021, Cellular and Molecular Life Sciences.

[69]  Qi-En Wang,et al.  Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor. , 2021, Journal of medicinal chemistry.

[70]  Y. Naaldijk,et al.  Rab GTPases in Parkinson's disease: a primer , 2021, Essays in biochemistry.

[71]  Hannah A. Blair.  Sotorasib: First Approval , 2021, Drugs.

[72]  S. Campbell,et al.  Post-translational modification of RAS proteins. , 2021, Current opinion in structural biology.

[73]  Yalei Zhang,et al.  Emerging strategies to target RAS signaling in human cancer therapy , 2021, Journal of Hematology & Oncology.

[74]  Gyu Rie Lee,et al.  Accurate prediction of protein structures and interactions using a 3-track neural network , 2021, Science.

[75]  Ryouko Kamata,et al.  Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification , 2021, Frontiers in Molecular Biosciences.

[76]  P. Jänne,et al.  Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer , 2021, Experimental and Molecular Therapeutics.

[77]  B. Garcia,et al.  Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting , 2021, Nature Communications.

[78]  Neal Rosen.  Finally, Effective Inhibitors of Mutant KRAS. , 2021, The New England journal of medicine.

[79]  H. Mott,et al.  Progress in the therapeutic inhibition of Cdc42 signalling , 2021, Biochemical Society transactions.

[80]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[81]  N. Tanaka,et al.  Kras activation in endometrial organoids drives cellular transformation and epithelial-mesenchymal transition , 2021, Oncogenesis.

[82]  L. Dall’Asta,et al.  Physics of compartmentalization: How phase separation and signaling shape membrane and organelle identity , 2021, Computational and structural biotechnology journal.

[83]  Shouzhen Chen,et al.  KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1 , 2021, Molecular cancer.

[84]  William Guiler,et al.  Pharmacological Modulators of Small GTPases of Rho Family in Neurodegenerative Diseases , 2021, Frontiers in Cellular Neuroscience.

[85]  B. Neel,et al.  Selective and noncovalent targeting of RAS mutants for inhibition and degradation , 2021, Nature Communications.

[86]  M. Fitzgerald,et al.  Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N-arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity , 2021, bioRxiv.

[87]  Z. Modrušan,et al.  ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma , 2021, Nature.

[88]  A. Gorfe,et al.  Monoubiquitination of KRAS at Lysine104 and Lysine147 Modulates Its Dynamics and Interaction with Partner Proteins. , 2021, The journal of physical chemistry. B.

[89]  P. Arora,et al.  A Sos proteomimetic as a pan-Ras inhibitor , 2021, Proceedings of the National Academy of Sciences.

[90]  R. Heist,et al.  Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. , 2021, Cancer discovery.

[91]  P. Takis,et al.  REP1 deficiency causes systemic dysfunction of lipid metabolism and oxidative stress in choroideremia , 2021, JCI insight.

[92]  Sung-Bae Kim,et al.  Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Frost,et al.  Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors. , 2021, European journal of medicinal chemistry.

[94]  P. Ettmayer,et al.  One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS. , 2021, Journal of medicinal chemistry.

[95]  Dan Liu,et al.  Unveiling the “invisible” druggable conformations of GDP-bound inactive Ras , 2021, Proceedings of the National Academy of Sciences.

[96]  Daniel S. Terry,et al.  Single-molecule FRET imaging of GPCR dimers in living cells , 2021, Nature Methods.

[97]  S. Powers,et al.  KRAS drives immune evasion in a genetic model of pancreatic cancer , 2021, Nature communications.

[98]  Michelle S. Miller,et al.  Bispecific antibodies targeting mutant RAS neoantigens , 2021, Science Immunology.

[99]  G. King,et al.  Trends in peptide drug discovery , 2021, Nature Reviews Drug Discovery.

[100]  E. Macia,et al.  Chlortetracycline, a Novel Arf Inhibitor That Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells , 2021, Molecules.

[101]  L. Kay,et al.  NMR spectroscopy captures the essential role of dynamics in regulating biomolecular function , 2021, Cell.

[102]  S. Schneider,et al.  Rab1-AMPylation by Legionella DrrA is allosterically activated by Rab1 , 2021, Nature communications.

[103]  Yue He,et al.  High expression of Rab31 confers a poor prognosis and enhances cell proliferation and invasion in oral squamous cell carcinoma , 2021, Oncology reports.

[104]  S. Schreiber.  The Rise of Molecular Glues , 2021, Cell.

[105]  Dianshui Sun,et al.  Overexpression of microRNA-19a-3p promotes lymph node metastasis of esophageal squamous cell carcinoma via the RAC1/CDC42-PAK1 pathway , 2021, Translational cancer research.

[106]  Shuhui Lim,et al.  Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States , 2020, ACS central science.

[107]  M. McPherson,et al.  RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site , 2020, bioRxiv.

[108]  Suryani Lukman,et al.  Structural dynamics and allostery of Rab proteins: strategies for drug discovery and design , 2020, Briefings Bioinform..

[109]  J. Guan,et al.  Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules , 2019, Cell.

[110]  Yaowen Wu.  Spatiotemporal Imaging of Small GTPase Activity Using Conformational Sensors for GTPase Activity (COSGA). , 2021, Methods in molecular biology.

[111]  Andrea Oeckinghaus,et al.  The RAL signaling network: Cancer and beyond. , 2021, International review of cell and molecular biology.

[112]  P. Hammerman,et al.  LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors , 2020, Clinical Cancer Research.

[113]  T. Hirokawa,et al.  Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo , 2020, Scientific Reports.

[114]  P. Brear,et al.  Affinity maturation of the RLIP76 Ral binding domain to inform the design of stapled peptides targeting the Ral GTPases , 2020, The Journal of biological chemistry.

[115]  J. Smiley,et al.  Endosomal Dysfunction Induced by Directly Overactivating Rab5 Recapitulates Prodromal and Neurodegenerative Features of Alzheimer's Disease. , 2020, Cell reports.

[116]  T. Brummer,et al.  Immune modulatory effects of oncogenic KRAS in cancer , 2020, Nature Communications.

[117]  S. Gygi,et al.  3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis. , 2020, Molecular cell.

[118]  P. Lito,et al.  Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients , 2020, Cell.

[119]  Pascale G. Charest,et al.  Ras, PI3K and mTORC2 – three's a crowd? , 2020, Journal of Cell Science.

[120]  Yusong R Guo,et al.  The amphipathic helices of Arfrp1 and Arl14 are sufficient to determine subcellular localizations , 2020, The Journal of Biological Chemistry.

[121]  K. Shokat,et al.  GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf , 2020, ACS central science.

[122]  Yuanzhong Wu,et al.  RAB31 marks and controls an ESCRT-independent exosome pathway , 2020, Cell Research.

[123]  G. Bergström,et al.  Lack of RAC1 in macrophages protects against atherosclerosis , 2020, PloS one.

[124]  T. Tan,et al.  Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[125]  P. Ettmayer,et al.  BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. , 2020, Cancer discovery.

[126]  M. Ikura,et al.  NMR in integrated biophysical drug discovery for RAS: past, present, and future , 2020, Journal of Biomolecular NMR.

[127]  A. Gorfe,et al.  KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface , 2020, iScience.

[128]  L. Kwong,et al.  Same Name, Different Game: EGFR Drives Intrinsic KRASG12C Inhibitor Resistance in Colorectal Cancer. , 2020, Cancer discovery.

[129]  E. Olejniczak,et al.  Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods. , 2020, Journal of medicinal chemistry.

[130]  M. Fukuda,et al.  A comprehensive analysis of Rab GTPases reveals a role for Rab34 in serum starvation-induced primary ciliogenesis , 2020, The Journal of Biological Chemistry.

[131]  Yan G Zhao,et al.  Phase Separation in Membrane Biology: The Interplay between Membrane-Bound Organelles and Membraneless Condensates. , 2020, Developmental cell.

[132]  Anthony Leyme,et al.  Revealing the Activity of Trimeric G-proteins in Live Cells with a Versatile Biosensor Design , 2020, Cell.

[133]  T. Rabbitts,et al.  A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS , 2020, Nature Communications.

[134]  C. Asquith,et al.  STK19: a new target for NRAS-driven cancer , 2020, Nature reviews. Drug discovery.

[135]  M. Fukuda,et al.  Rab family of small GTPases: an updated view on their regulation and functions , 2020, The FEBS journal.

[136]  F. McCormick,et al.  RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.

[137]  A. Mes-Masson,et al.  Ran GTPase: A Key Player in Tumor Progression and Metastasis , 2020, Frontiers in Cell and Developmental Biology.

[138]  N. Rosen,et al.  EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. , 2020, Cancer discovery.

[139]  Kaixian Chen,et al.  Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion , 2020, Advanced science.

[140]  Sourav Bandyopadhyay,et al.  Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility , 2020, Nature Communications.

[141]  M. Boutros,et al.  Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids. , 2020, Cell stem cell.

[142]  C. Casalou,et al.  The Role of ARF Family Proteins and Their Regulators and Effectors in Cancer Progression: A Therapeutic Perspective , 2020, Frontiers in Cell and Developmental Biology.

[143]  C. Crews,et al.  Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs , 2020, ACS central science.

[144]  P. Fossa,et al.  Charcot-Marie-Tooth Type 2B: A New Phenotype Associated with a Novel RAB7A Mutation and Inhibited EGFR Degradation , 2020, Cells.

[145]  X. Wang,et al.  Regulation of the small GTPase Ran by miR-802 modulates proliferation and metastasis in colorectal cancer cells , 2020, British Journal of Cancer.

[146]  H. Yao,et al.  Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer , 2020, Nature Communications.

[147]  J. Desai,et al.  Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  Scott W. Simpkins,et al.  CRISPR screens in cancer spheroids identify 3D growth specific vulnerabilities , 2020, Nature.

[149]  Z. Meng,et al.  Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine , 2020, Clinical Cancer Research.

[150]  David A. Scott,et al.  An open-source drug discovery platform enables ultra-large virtual screens , 2020, Nature.

[151]  Julia M. Shifman,et al.  RASSF effectors couple diverse RAS subfamily GTPases to the Hippo pathway , 2020, Science Signaling.

[152]  Z. Tümer,et al.  A Missense Mutation in RAB28 in a Family with Cone-Rod Dystrophy and Postaxial Polydactyly Prevents Localization of RAB28 to the Primary Cilium , 2020, Investigative Ophthalmology and Visual Science.

[153]  Andrew B Singleton,et al.  The genetic architecture of Parkinson's disease , 2020, The Lancet Neurology.

[154]  A. Morrison,et al.  Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[155]  R. Cooley,et al.  The discovery and maturation of peptide biologics targeting the small G-protein Cdc42: A bioblockade for Ras-driven signaling , 2020, The Journal of Biological Chemistry.

[156]  Davide Risso,et al.  Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition , 2020, Nature.

[157]  Prabhakar R. Gudla,et al.  Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior , 2020, eLife.

[158]  R. Sidbury,et al.  RASopathies. , 2020, Clinics in dermatology.

[159]  E. Ropelle,et al.  Rock protein as cardiac hypertrophy modulator in obesity and physical exercise. , 2020, Life sciences.

[160]  R. Borgatti,et al.  Pain‐related increase in serotonin transporter gene methylation associates with emotional regulation in 4.5‐year‐old preterm‐born children , 2019, Acta paediatrica.

[161]  F. Cheng,et al.  Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. , 2019, The Journal of clinical investigation.

[162]  David A. Scott,et al.  Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. , 2019, Cell chemical biology.

[163]  Amy M. Hurwitz,et al.  DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. , 2019, Cell reports.

[164]  A. Balmain,et al.  KRAS4A Directly Regulates Hexokinase 1 , 2019, Nature.

[165]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[166]  Joshua M. Dempster,et al.  Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. , 2019, Cell reports.

[167]  G. Curigliano,et al.  Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review. , 2019, JAMA oncology.

[168]  D. Ward,et al.  Identification of a new inhibitor of KRAS‐PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer , 2019, International journal of cancer.

[169]  Zhixiang Wang,et al.  Rac1 S71 Mediates the Interaction between Rac1 and 14-3-3 Proteins , 2019, Cells.

[170]  V. Baekelandt,et al.  RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase–mediated centrosomal cohesion and ciliogenesis deficits , 2019, Human molecular genetics.

[171]  J. Heymach,et al.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.

[172]  Amit K. Gupta,et al.  Multi‐target, ensemble‐based virtual screening yields novel allosteric KRAS inhibitors at high success rate , 2019, Chemical biology & drug design.

[173]  Gabriella Siszler,et al.  KRAS Binders Hidden in Nature , 2019, Chemistry.

[174]  Sophie G. Martin,et al.  Optogenetics reveals Cdc42 local activation by scaffold-mediated positive feedback and Ras GTPase , 2019, bioRxiv.

[175]  M. Koegl,et al.  Drugging an undruggable pocket on KRAS , 2019, Proceedings of the National Academy of Sciences.

[176]  R. Neubig,et al.  RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance , 2019, Cancer cell.

[177]  Yulin Wang,et al.  ARL3 is downregulated and acts as a prognostic biomarker in glioma , 2019, Journal of Translational Medicine.

[178]  Qian Yang,et al.  Small GTPase Arf6 regulates diabetes‐induced cholesterol accumulation in podocytes , 2019, Journal of cellular physiology.

[179]  P. Kolasinska-Zwierz,et al.  KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe , 2019, Nature Communications.

[180]  Wen-quan Wang,et al.  SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer , 2019, Journal of Cancer.

[181]  S. Baek,et al.  Neurodevelopmental Aspects of RASopathies , 2019, Molecules and cells.

[182]  J. Cherfils,et al.  ARF GTPases and their GEFs and GAPs: concepts and challenges , 2019, Molecular biology of the cell.

[183]  K. Shokat,et al.  Bifunctional Small Molecule Ligands of K-Ras Induce Its Association with Immunophilin Proteins , 2019, bioRxiv.

[184]  R. Rabadán,et al.  Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. , 2019, Cancer cell.

[185]  Parantu K. Shah,et al.  Applications of machine learning in drug discovery and development , 2019, Nature Reviews Drug Discovery.

[186]  H. Ovaa,et al.  USP32 regulates late endosomal transport and recycling through deubiquitylation of Rab7 , 2019, Nature Communications.

[187]  Yaxue Zhao,et al.  Inhibition of Cdc42–intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth , 2019, Cancer biology & therapy.

[188]  J. Groves,et al.  A molecular assembly phase transition and kinetic proofreading modulate Ras activation by SOS , 2019, Science.

[189]  E. Petricoin,et al.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer , 2019, Nature Medicine.

[190]  R. Yaeger,et al.  Targeting Alterations in the RAF-MEK Pathway. , 2019, Cancer discovery.

[191]  M. Isreb,et al.  Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo , 2019, Cancers.

[192]  J. Hanrahan,et al.  The Role of KRAS in Endometrial Cancer: A Mini-Review , 2019, AntiCancer Research.

[193]  G. Wei,et al.  Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis , 2019, Cell.

[194]  S. Phillips,et al.  Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds , 2019, Proceedings of the National Academy of Sciences.

[195]  H. Briem,et al.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.

[196]  J. Yap,et al.  Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.

[197]  M. Ikura,et al.  Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation , 2019, Nature Communications.

[198]  C. Holt,et al.  Late Endosomes Act as mRNA Translation Platforms and Sustain Mitochondria in Axons , 2019, Cell.

[199]  Robin T. Varghese,et al.  Functional Blockade of Small GTPase RAN Inhibits Glioblastoma Cell Viability , 2019, Front. Oncol..

[200]  Kunihiro Matsumoto,et al.  LRRK1 phosphorylation of Rab7 at S72 links trafficking of EGFR-containing endosomes to its effector RILP , 2019, Journal of Cell Science.

[201]  R. Neubig,et al.  RAC1 P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance , 2019 .

[202]  D. Tuveson,et al.  Oncogenic Kras induces Nix-mediated mitophagy to promote pancreatic cancer. , 2019, Cancer discovery.

[203]  D. Sabatini,et al.  RAB7A phosphorylation by TBK1 promotes mitophagy via the PINK-PARKIN pathway , 2018, Science Advances.

[204]  W. Jahnke,et al.  Inhibition of K-RAS4B by a Unique Mechanism of Action: Stabilizing Membrane-Dependent Occlusion of the Effector-Binding Site. , 2018, Cell chemical biology.

[205]  M. Philips,et al.  Posttranslational Modifications of RAS Proteins. , 2018, Cold Spring Harbor perspectives in medicine.

[206]  Mazhar Adli,et al.  CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response , 2018, Nature Communications.

[207]  Jin Liu,et al.  CID1067700, a late endosome GTPase Rab7 receptor antagonist, attenuates brain atrophy, improves neurologic deficits and inhibits reactive astrogliosis in rat ischemic stroke , 2018, Acta Pharmacologica Sinica.

[208]  Priyanka Prakash,et al.  Ras and the Plasma Membrane: A Complicated Relationship. , 2018, Cold Spring Harbor perspectives in medicine.

[209]  N. Nassar,et al.  Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization , 2018, Leukemia.

[210]  W. Dai,et al.  K-Ras Lys-42 is crucial for its signaling, cell migration, and invasion , 2018, The Journal of Biological Chemistry.

[211]  S. Fesik,et al.  Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS. , 2018, Journal of medicinal chemistry.

[212]  F. Zhou,et al.  CSTF2-Induced Shortening of the RAC1 3'UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder. , 2018, Cancer research.

[213]  Robert V Farese,et al.  Rab18 is not necessary for lipid droplet biogenesis or turnover in human mammary carcinoma cells , 2018, Molecular biology of the cell.

[214]  Narcis Fernandez-Fuentes,et al.  Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment , 2018, Nature Communications.

[215]  S. Fesik,et al.  Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS. , 2018, ACS medicinal chemistry letters.

[216]  P. Lito,et al.  A treatment strategy for KRAS-driven tumors , 2018, Nature Medicine.

[217]  A. Yart,et al.  The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway. , 2018, Endocrine reviews.

[218]  S. Lukman,et al.  Allosteric binding sites in Rab11 for potential drug candidates , 2018, PloS one.

[219]  María del Mar Maldonado,et al.  Targeting Rac and Cdc42 GTPases in Cancer. , 2018, Cancer research.

[220]  S. Fesik,et al.  Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling. , 2018, Journal of medicinal chemistry.

[221]  R. Bernards,et al.  SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo , 2018, Nature Medicine.

[222]  W. Birchmeier,et al.  Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase , 2018, Nature Medicine.

[223]  Zhixian He,et al.  Knockdown of Ran GTPase expression inhibits the proliferation and migration of breast cancer cells , 2018, Molecular medicine reports.

[224]  S. Fesik,et al.  High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. , 2018, Analytical biochemistry.

[225]  P. Hiesinger,et al.  Rab GTPases and Membrane Trafficking in Neurodegeneration , 2018, Current Biology.

[226]  B. Neumann,et al.  A RAB35-p85/PI3K axis controls oscillatory apical protrusions required for efficient chemotactic migration , 2018, Nature Communications.

[227]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[228]  James M. McFarland,et al.  Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2 , 2018, Nature Medicine.

[229]  R. Bast,et al.  RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells , 2018, Autophagy.

[230]  Kenta Ito,et al.  Prognostic impacts of Rho-kinase activity in circulating leucocytes in patients with vasospastic angina , 2018, European heart journal.

[231]  S. Maddika,et al.  Post translational modifications of Rab GTPases , 2018, Small GTPases.

[232]  D. Pei,et al.  Targeting Ras with Macromolecules. , 2018, Cold Spring Harbor perspectives in medicine.

[233]  M. Barbacid,et al.  c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. , 2018, Cancer cell.

[234]  A. Ridley,et al.  Rho GTPase signaling complexes in cell migration and invasion , 2018, The Journal of cell biology.

[235]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[236]  D. Barbie,et al.  RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic? , 2018, Clinical Cancer Research.

[237]  D. Theodorescu,et al.  RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer , 2018, Pharmacological Reviews.

[238]  W. Dai,et al.  RAS GTPases are modified by SUMOylation , 2017, Oncotarget.

[239]  Manish R. Patel,et al.  First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. , 2017, Cancer discovery.

[240]  X. Yao,et al.  Mitosis-specific acetylation tunes Ran effector binding for chromosome segregation , 2017, Journal of molecular cell biology.

[241]  A. Houdusse,et al.  Rab GTPases and their interacting protein partners: Structural insights into Rab functional diversity , 2017, Small GTPases.

[242]  M. Olson.  Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors , 2016, Small GTPases.

[243]  M. Oliveira,et al.  KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment. , 2018, Cancer research.

[244]  G. Verdine,et al.  Exceptionally high-affinity Ras binders that remodel its effector domain , 2017, The Journal of Biological Chemistry.

[245]  Q. Lu,et al.  Rho GTPases as therapeutic targets in Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[246]  B. Taylor,et al.  EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer , 2017, Nature Communications.

[247]  E. Levy,et al.  Understanding Chylomicron Retention Disease Through Sar1b Gtpase Gene Disruption: Insight From Cell Culture , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[248]  G. Evan,et al.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression , 2017, Cell.

[249]  T. Rana,et al.  Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers. , 2017, Cancer research.

[250]  Matthias Mann,et al.  Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis , 2017, eLife.

[251]  S. Lefrancois,et al.  Post-translational modifications: How to modulate Rab7 functions , 2017, Small GTPases.

[252]  M. Ladanyi,et al.  Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[253]  T. Pluard,et al.  Ral signaling pathway in health and cancer , 2017, Cancer medicine.

[254]  C. Brangwynne,et al.  Liquid phase condensation in cell physiology and disease , 2017, Science.

[255]  J. Cherfils,et al.  Family-wide Analysis of the Inhibition of Arf Guanine Nucleotide Exchange Factors with Small Molecules: Evidence of Unique Inhibitory Profiles. , 2017, Biochemistry.

[256]  Y. Ouyang,et al.  RABIF/MSS4 is a Rab-stabilizing holdase chaperone required for GLUT4 exocytosis , 2017, Proceedings of the National Academy of Sciences.

[257]  Zhaoxia Sun,et al.  Palmitoylation of the ciliary GTPase ARL13b is necessary for its stability and its role in cilia formation , 2017, The Journal of Biological Chemistry.

[258]  T. Katada,et al.  Regulation of the Sar1 GTPase Cycle Is Necessary for Large Cargo Secretion from the Endoplasmic Reticulum , 2017, Front. Cell Dev. Biol..

[259]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[260]  C. Yip,et al.  Rab7 palmitoylation is required for efficient endosome-to-TGN trafficking , 2017, Journal of Cell Science.

[261]  Chunhong Hu,et al.  Rab25 GTPase: Functional roles in cancer , 2017, Oncotarget.

[262]  Jing Zhang,et al.  Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange , 2017, Nature Communications.

[263]  K Dane Wittrup,et al.  An engineered protein antagonist of K-Ras/B-Raf interaction , 2017, Scientific Reports.

[264]  Frank McCormick,et al.  RAS Proteins and Their Regulators in Human Disease , 2017, Cell.

[265]  K. Shokat,et al.  Drugging the 'undruggable' cancer targets , 2017, Nature Reviews Cancer.

[266]  W. Hahn,et al.  A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas , 2017, Neuro-oncology.

[267]  S. Sogabe,et al.  Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d. , 2017, ACS medicinal chemistry letters.

[268]  A. Wittinghofer,et al.  Structure-based development of PDEδ inhibitors , 2017, Biological chemistry.

[269]  P. McCarron,et al.  Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells. , 2017, International journal of pharmaceutics.

[270]  R. Zare,et al.  Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma , 2017, Proceedings of the National Academy of Sciences.

[271]  Beibei Chen,et al.  High expression of Rab25 contributes to malignant phenotypes and biochemical recurrence in patients with prostate cancer after radical prostatectomy , 2017, Cancer Cell International.

[272]  Zhenjiang Li,et al.  Knockdown of Ras-Related Protein 25 (Rab25) Inhibits the In Vitro Cytotoxicity and In Vivo Antitumor Activity of Human Glioblastoma Multiforme Cells. , 2017, Oncology research.

[273]  Kotaro Sakamoto,et al.  K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology. , 2017, Biochemical and biophysical research communications.

[274]  Toru Suzuki,et al.  Inhibition of KLF5–Myo9b–RhoA Pathway–Mediated Podosome Formation in Macrophages Ameliorates Abdominal Aortic Aneurysm , 2017, Circulation research.

[275]  Matthew E. Welsch,et al.  Multivalent Small-Molecule Pan-RAS Inhibitors , 2017, Cell.

[276]  Anthony A. Hyman,et al.  Biomolecular condensates: organizers of cellular biochemistry , 2017, Nature Reviews Molecular Cell Biology.

[277]  R. Roberts,et al.  RasIns: Genetically Encoded Intrabodies of Activated Ras Proteins. , 2017, Journal of molecular biology.

[278]  Xiaomin Luo,et al.  COPI–TRAPPII activates Rab18 and regulates its lipid droplet association , 2017, The EMBO journal.

[279]  Hiroaki Suga,et al.  A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets. , 2017, Chemical communications.

[280]  Eric S. Lander,et al.  Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras , 2017, Cell.

[281]  C. Der,et al.  A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation* , 2017, The Journal of Biological Chemistry.

[282]  P. Bastiaens,et al.  A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2. , 2017, Angewandte Chemie.

[283]  Priyanka Prakash,et al.  Lipid-Sorting Specificity Encoded in K-Ras Membrane Anchor Regulates Signal Output , 2017, Cell.

[284]  U. Laufs,et al.  Pleiotropic Effects of Statins on the Cardiovascular System , 2017, Circulation research.

[285]  B. Taylor,et al.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.

[286]  Marc Therrien,et al.  Inhibition of RAS function through targeting an allosteric regulatory site. , 2017, Nature chemical biology.

[287]  Juanita Lopez,et al.  Combine and conquer: challenges for targeted therapy combinations in early phase trials , 2017, Nature Reviews Clinical Oncology.

[288]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[289]  I. Matic,et al.  Phosphoribosylation of Ubiquitin Promotes Serine Ubiquitination and Impairs Conventional Ubiquitination , 2016, Cell.

[290]  M. Mann,et al.  C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons , 2016, Nature Neuroscience.

[291]  R. Morgan,et al.  Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling , 2016, Oncotarget.

[292]  H. Donninger,et al.  Ras signaling through RASSF proteins. , 2016, Seminars in cell & developmental biology.

[293]  Mikaël M. Martino,et al.  Bone-protective Functions of Netrin 1 Protein* , 2016, The Journal of Biological Chemistry.

[294]  L. Stone.  Bladder cancer: Rho-sensitive pathway mediates metastasis , 2016, Nature Reviews Urology.

[295]  A. Ridley,et al.  Rho GTPases: Regulation and roles in cancer cell biology , 2016, Small GTPases.

[296]  M. Herlyn,et al.  An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. , 2016, Cancer cell.

[297]  A. Faustino,et al.  Arf proteins in cancer cell migration , 2016, Small GTPases.

[298]  Martin L. Miller,et al.  Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma. , 2016, Cancer discovery.

[299]  Xiayang Xie,et al.  Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1 , 2016, Oncotarget.

[300]  R. Deberardinis,et al.  Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. , 2016, Cell reports.

[301]  K. Shokat,et al.  Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design , 2016, Nature Reviews Drug Discovery.

[302]  P. Novick.  Regulation of membrane traffic by Rab GEF and GAP cascades , 2016, Small GTPases.

[303]  A. Armstrong,et al.  RAC1 activation drives pathologic interactions between the epidermis and immune cells. , 2016, The Journal of clinical investigation.

[304]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[305]  K. Dutta,et al.  A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling , 2016, Cell.

[306]  P. Bastiaens,et al.  Identification of pyrazolopyridazinones as PDEδ inhibitors , 2016, Nature Communications.

[307]  Yu Pan,et al.  RCC1-dependent activation of Ran accelerates cell cycle and DNA repair, inhibiting DNA damage–induced cell senescence , 2016, Molecular biology of the cell.

[308]  S. Gabriel,et al.  Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.

[309]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[310]  Zhao‐Qing Luo,et al.  Ubiquitination independent of E1 and E2 enzymes by bacterial effectors , 2016, Nature.

[311]  D. Krainc,et al.  Parkin Modulates Endosomal Organization and Function of the Endo-Lysosomal Pathway , 2016, Journal of Neuroscience.

[312]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[313]  Q. Feng,et al.  A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues , 2016, BMC Cancer.

[314]  S. Maddika,et al.  PTEN modulates EGFR late endocytic trafficking and degradation by dephosphorylating Rab7 , 2016, Nature Communications.

[315]  Dean Y. Li,et al.  Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis , 2016, Molecular oncology.

[316]  Matthias Mann,et al.  Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases , 2016, eLife.

[317]  Ozlem Keskin,et al.  Ras Conformational Ensembles, Allostery, and Signaling. , 2016, Chemical reviews.

[318]  Khalid W. Kalim,et al.  Inactivating Mutations in GNA13 and RHOA in Burkitt’s Lymphoma and Diffuse Large B cell Lymphoma: A Tumor Suppressor Function for the Gα13/RhoA Axis in B Cells , 2015, Oncogene.

[319]  Junnian Zheng,et al.  PLCε signaling in cancer , 2016, Journal of Cancer Research and Clinical Oncology.

[320]  Kang-Yell Choi,et al.  The pleckstrin homology domain of phospholipase D1 accelerates EGFR endocytosis by increasing the expression of the Rab5 effector, rabaptin-5 , 2015, Experimental & Molecular Medicine.

[321]  B. Raught,et al.  Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis , 2015, Nature Communications.

[322]  J. Li,et al.  Increased Expression of Rac1 in Epilepsy Patients and Animal Models , 2015, Neurochemical Research.

[323]  J. Li,et al.  Expression of Ras-related protein 25 predicts chemotherapy resistance and prognosis in advanced non-small cell lung cancer. , 2015, Genetics and molecular research : GMR.

[324]  J. Corvol,et al.  Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1 , 2015, The EMBO journal.

[325]  P. Knyphausen,et al.  Lysine-acetylation as a fundamental regulator of Ran function: Implications for signaling of proteins of the Ras-superfamily , 2015, Small GTPases.

[326]  D. Sabatini,et al.  Identification of an oncogenic RAB protein , 2015, Science.

[327]  O. Abdel-Wahab,et al.  BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.

[328]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[329]  Harald Stenmark,et al.  Cellular functions of Rab GTPases at a glance , 2015, Journal of Cell Science.

[330]  D. Ann,et al.  Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype , 2015, Scientific Reports.

[331]  Yi Zheng,et al.  Approaches of targeting Rho GTPases in cancer drug discovery , 2015, Expert opinion on drug discovery.

[332]  A. Azad,et al.  Which Way In? The RalF Arf-GEF Orchestrates Rickettsia Host Cell Invasion , 2015, PLoS pathogens.

[333]  K. Corbett,et al.  Tubulin cofactors and Arl2 are cage-like chaperones that regulate the soluble αβ-tubulin pool for microtubule dynamics , 2015, eLife.

[334]  C. Burrows,et al.  A Role for the Fifth G-Track in G-Quadruplex Forming Oncogene Promoter Sequences during Oxidative Stress: Do These “Spare Tires” Have an Evolved Function? , 2015, ACS central science.

[335]  J. Brown,et al.  G Protein–Coupled Receptor and RhoA-Stimulated Transcriptional Responses: Links to Inflammation, Differentiation, and Cell Proliferation , 2015, Molecular Pharmacology.

[336]  M. Krüger,et al.  Small GTP-binding protein Ran is regulated by posttranslational lysine acetylation , 2015, Proceedings of the National Academy of Sciences.

[337]  Gudrun Schleiermacher,et al.  Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.

[338]  Sarah R. Clippinger,et al.  Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides. , 2015, Angewandte Chemie.

[339]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[340]  Mark T. Handley,et al.  Warburg Micro syndrome is caused by RAB18 deficiency or dysregulation , 2015, Open Biology.

[341]  S. Hersch,et al.  Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington’s Disease , 2015, Molecular Neurobiology.

[342]  I. Zerr,et al.  Creutzfeldt-Jakob Disease Subtype-Specific Regional and Temporal Regulation of ADP Ribosylation Factor-1-Dependent Rho/MLC Pathway at Pre-Clinical Stage , 2015, Journal of Molecular Neuroscience.

[343]  C. Der,et al.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? , 2015, Clinical Cancer Research.

[344]  Q. Jia,et al.  Rab25 upregulation correlates with the proliferation, migration, and invasion of renal cell carcinoma. , 2015, Biochemical and biophysical research communications.

[345]  X. Wang,et al.  Inhibition of the small GTPase Cdc42 in regulation of epileptic-seizure in rats , 2015, Neuroscience.

[346]  S. Spanò,et al.  The small GTPase Rab29 is a common regulator of immune synapse assembly and ciliogenesis , 2015, Cell Death and Differentiation.

[347]  M. Way,et al.  KSHV‐TK is a tyrosine kinase that disrupts focal adhesions and induces Rho‐mediated cell contraction , 2015, The EMBO journal.

[348]  J. Cherfils,et al.  On the use of Legionella/Rickettsia chimeras to investigate the structure and regulation of Rickettsia effector RalF. , 2015, Journal of structural biology.

[349]  Norbert Perrimon,et al.  Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices , 2015, Proceedings of the National Academy of Sciences.

[350]  S. Chia,et al.  Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. , 2015, Current oncology.

[351]  B. Tang,et al.  The role of the small GTPase Rab31 in cancer , 2014, Journal of cellular and molecular medicine.

[352]  Joshua D. Rabinowitz,et al.  The return of metabolism: biochemistry and physiology of the pentose phosphate pathway , 2014, Biological reviews of the Cambridge Philosophical Society.

[353]  J. Brown,et al.  PLCε mediated sustained signaling pathways. , 2015, Advances in biological regulation.

[354]  P. Lockhart,et al.  Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. , 2014, American journal of human genetics.

[355]  J. Cherfils.  Arf GTPases and their effectors: assembling multivalent membrane-binding platforms. , 2014, Current opinion in structural biology.

[356]  H. Shimokawa,et al.  Rho-Kinase Inhibition Ameliorates Metabolic Disorders through Activation of AMPK Pathway in Mice , 2014, PloS one.

[357]  Se Jin Park,et al.  HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer. , 2014, Cancer letters.

[358]  Y. Jiang,et al.  Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions , 2014, Cell Death and Disease.

[359]  Edgars Celms,et al.  Variation in genomic landscape of clear cell renal cell carcinoma across Europe , 2014, Nature Communications.

[360]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[361]  J. Rodríguez-Orengo,et al.  The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model , 2014, Translational oncology.

[362]  C. L. Jackson,et al.  Arfs at a Glance , 2014, Journal of Cell Science.

[363]  David L. Brautigan,et al.  Discovery and characterization of small molecules that target the GTPase Ral , 2014, Nature.

[364]  B. Raught,et al.  Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation , 2014, Proceedings of the National Academy of Sciences.

[365]  G. Ding,et al.  Rab25 expression predicts poor prognosis in clear cell renal cell carcinoma , 2014, Experimental and therapeutic medicine.

[366]  John C Hunter,et al.  In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C , 2014, Proceedings of the National Academy of Sciences.

[367]  Colin A. Johnson,et al.  Unraveling the genetics of Joubert and Meckel-Gruber syndromes , 2014, Journal of Pediatric Genetics.

[368]  Atsushi Tanaka,et al.  Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma , 2014, Nature Genetics.

[369]  Su-zhan Zhang,et al.  Cytohesins/ARNO: The Function in Colorectal Cancer Cells , 2014, PloS one.

[370]  Min Kyung Sung,et al.  A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.

[371]  E. Olejniczak,et al.  Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange , 2014, Proceedings of the National Academy of Sciences.

[372]  A. Represa,et al.  TBC1D24 regulates neuronal migration and maturation through modulation of the ARF6-dependent pathway , 2014, Proceedings of the National Academy of Sciences.

[373]  O. Nureki,et al.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.

[374]  I. Lossos,et al.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas , 2014, Nature Genetics.

[375]  Taebo Sim,et al.  Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. , 2014, Angewandte Chemie.

[376]  A. Minden,et al.  P21 activated kinases , 2014, Small GTPases.

[377]  S. Angers,et al.  Ubiquitylation and activation of a Rab GTPase is promoted by a &bgr;2AR–HACE1 complex , 2014, Journal of Cell Science.

[378]  D. Hallahan,et al.  Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma , 2013, Oncogene.

[379]  Wei Liu,et al.  Ran GTPase induces EMT and enhances invasion in non-small cell lung cancer cells through activation of PI3K-AKT pathway. , 2014, Oncology research.

[380]  J. Chernoff,et al.  PAK signalling during the development and progression of cancer , 2013, Nature Reviews Cancer.

[381]  Roland Seifert,et al.  Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .

[382]  Yutong Zhao,et al.  A new mechanism of RhoA ubiquitination and degradation: roles of SCF(FBXL19) E3 ligase and Erk2. , 2013, Biochimica et biophysica acta.

[383]  S. Cevik,et al.  Active Transport and Diffusion Barriers Restrict Joubert Syndrome-Associated ARL13B/ARL-13 to an Inv-like Ciliary Membrane Subdomain , 2013, PLoS genetics.

[384]  T. Lucas,et al.  Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity , 2013, Journal of Translational Medicine.

[385]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[386]  H. Dohlman,et al.  Differences in the Regulation of K-Ras and H-Ras Isoforms by Monoubiquitination* , 2013, The Journal of Biological Chemistry.

[387]  J. Rothstein,et al.  RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia , 2013, Proceedings of the National Academy of Sciences.

[388]  Chenhui Lu,et al.  Expression of Rab25 correlates with the invasion and metastasis of gastric cancer. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[389]  D. Xie,et al.  Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial-mesenchymal transition and activation of Akt/GSK-3β/Snail signaling. , 2013, Carcinogenesis.

[390]  H. Martin,et al.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. , 2013, The Journal of clinical investigation.

[391]  T. Lucas,et al.  A Rac1/Cdc42 GTPase-Specific Small Molecule Inhibitor Suppresses Growth of Primary Human Prostate Cancer Xenografts and Prolongs Survival in Mice , 2013, PloS one.

[392]  K. Krzewski,et al.  Evidence for defective Rab GTPase-dependent cargo traffic in immune disorders. , 2013, Experimental cell research.

[393]  M. Symons,et al.  Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression , 2013, Front. Oncol..

[394]  P. Sorensen,et al.  Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes , 2013, Nature Communications.

[395]  J. Briggs,et al.  Vesicle coats: structure, function, and general principles of assembly. , 2013, Trends in cell biology.

[396]  K. Haigis,et al.  HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS , 2013, Molecular Cancer Research.

[397]  P. Bastiaens,et al.  Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling , 2013, Nature.

[398]  Jiro Shimada,et al.  In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction , 2013, Proceedings of the National Academy of Sciences.

[399]  M. Noble,et al.  Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells , 2013, EMBO molecular medicine.

[400]  C. Berking,et al.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.

[401]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[402]  Nisha S. Sipes,et al.  Small-molecule inhibitors targeting G-protein–coupled Rho guanine nucleotide exchange factors , 2013, Proceedings of the National Academy of Sciences.

[403]  Winnie S. Liang,et al.  Reduced RAN Expression and Disrupted Transport between Cytoplasm and Nucleus; A Key Event in Alzheimer’s Disease Pathophysiology , 2013, PloS one.

[404]  Yaxue Zhao,et al.  Small molecule targeting Cdc42–intersectin interaction disrupts Golgi organization and suppresses cell motility , 2013, Proceedings of the National Academy of Sciences.

[405]  Matthew J. Davis,et al.  RAC1P29S is a spontaneously activating cancer-associated GTPase , 2013, Proceedings of the National Academy of Sciences.

[406]  Steven M. Lewis,et al.  Site–Specific Monoubiquitination Activates Ras by Impeding GTPase Activating Protein Function , 2012, Nature Structural &Molecular Biology.

[407]  Jacqueline Cherfils,et al.  Regulation of small GTPases by GEFs, GAPs, and GDIs. , 2013, Physiological reviews.

[408]  F. McCormick,et al.  Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. , 2013, Cancer discovery.

[409]  T. Simmen,et al.  Rab proteins of the endoplasmic reticulum: functions and interactors. , 2012, Biochemical Society transactions.

[410]  Jinghua Hu,et al.  SUMOylation of the small GTPase ARL-13 promotes ciliary targeting of sensory receptors , 2012, The Journal of cell biology.

[411]  V. Sheen.  Periventricular Heterotopia: Shuttling of Proteins through Vesicles and Actin in Cortical Development and Disease , 2012, Scientifica.

[412]  F. Shao,et al.  Structurally Distinct Bacterial TBC-like GAPs Link Arf GTPase to Rab1 Inactivation to Counteract Host Defenses , 2012, Cell.

[413]  Jeffrey S. Hannam,et al.  Anti-Proliferative Effect of Cytohesin Inhibition in Gefitinib-Resistant Lung Cancer Cells , 2012, PloS one.

[414]  D. Radisky,et al.  Matrix Metalloproteinase Induction of Rac1b, a Key Effector of Lung Cancer Progression , 2012, Science Translational Medicine.

[415]  Qi Sun,et al.  Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. , 2012, Angewandte Chemie.

[416]  Eric T. Kim,et al.  Regulation of RAS oncogenicity by acetylation , 2012, Proceedings of the National Academy of Sciences.

[417]  Yi Zheng,et al.  Essential Role of Cdc42 in Ras-Induced Transformation Revealed by Gene Targeting , 2012, PloS one.

[418]  Tudor I. Oprea,et al.  A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. , 2012, ACS chemical biology.

[419]  P. Novick,et al.  GTPase networks in membrane traffic. , 2012, Annual review of biochemistry.

[420]  Philippe P Roux,et al.  Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases , 2012, Microbiology and Molecular Reviews.

[421]  Yongxiang Yin,et al.  Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis , 2012, Tumor Biology.

[422]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[423]  M. Symons,et al.  Cdc42 and the Guanine Nucleotide Exchange Factors Ect2 and Trio Mediate Fn14-Induced Migration and Invasion of Glioblastoma Cells , 2012, Molecular Cancer Research.

[424]  L. Fang,et al.  Coptisine exert cardioprotective effect through anti-oxidative and inhibition of RhoA/Rho kinase pathway on isoproterenol-induced myocardial infarction in rats. , 2012, Atherosclerosis.

[425]  P. Xie,et al.  The Vasorelaxant Mechanisms of a Rho Kinase Inhibitor DL0805 in Rat Thoracic Aorta , 2012, Molecules.

[426]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[427]  R. Goody,et al.  Reversible phosphocholination of Rab proteins by Legionella pneumophila effector proteins , 2012, The EMBO journal.

[428]  H. Farhan,et al.  Crosstalk of small GTPases at the Golgi apparatus , 2012, Small GTPases.

[429]  I. Mellman,et al.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.

[430]  R. Goody,et al.  Posttranslational modifications of Rab proteins cause effective displacement of GDP dissociation inhibitor , 2012, Proceedings of the National Academy of Sciences.

[431]  L. Cubano,et al.  Characterization of EHop-016, Novel Small Molecule Inhibitor of Rac GTPase* , 2012, The Journal of Biological Chemistry.

[432]  M. Ruonala,et al.  IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation , 2012, The EMBO journal.

[433]  P. Bastiaens,et al.  The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins , 2011, Nature Cell Biology.

[434]  T. Katoh,et al.  Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library. , 2011, Chemistry & biology.

[435]  E. Borden,et al.  Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects , 2011, Oncotarget.

[436]  J. Bertoglio,et al.  The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active Rac1. , 2011, Developmental cell.

[437]  Yi Zheng,et al.  Cdc42 in oncogenic transformation, invasion, and tumorigenesis. , 2011, Cellular signalling.

[438]  J. Galán,et al.  Modulation of Rab GTPase function by a protein phosphocholine transferase , 2011, Nature.

[439]  Paramjit S. Arora,et al.  An Orthosteric Inhibitor of the Ras-Sos Interaction , 2011, Nature chemical biology.

[440]  B. Tang,et al.  Involvement of members of the Rab family and related small GTPases in autophagosome formation and maturation , 2011, Cellular and Molecular Life Sciences.

[441]  I. Vetter,et al.  Structure-function relationships of the G domain, a canonical switch motif. , 2011, Annual review of biochemistry.

[442]  C. L. Jackson,et al.  ARF family G proteins and their regulators: roles in membrane transport, development and disease , 2011, Nature Reviews Molecular Cell Biology.

[443]  Marc Liesa,et al.  Pancreatic cancers require autophagy for tumor growth. , 2011, Genes & development.

[444]  P. Pandolfi,et al.  Ubiquitination of K-Ras Enhances Activation and Facilitates Binding to Select Downstream Effectors , 2011, Science Signaling.

[445]  A. Fernández-Medarde,et al.  Ras in cancer and developmental diseases. , 2011, Genes & cancer.

[446]  Philippe P Roux,et al.  Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases , 2011, Microbiology and Molecular Reviews.

[447]  H. Coller,et al.  Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. , 2011, Genes & development.

[448]  R. Goody,et al.  GTPases involved in vesicular trafficking: structures and mechanisms. , 2011, Seminars in cell & developmental biology.

[449]  Li‐Jiau Huang,et al.  Signaling mechanisms of inhibition of phospholipase D activation by CHS-111 in formyl peptide-stimulated neutrophils. , 2011, Biochemical pharmacology.

[450]  S. Rodriguez-Zas,et al.  Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival , 2011, BMC Medical Genomics.

[451]  R. Schiff,et al.  Compartmentalized Ras Proteins Transform NIH 3T3 Cells with Different Efficiencies , 2010, Molecular and Cellular Biology.

[452]  J. Cherfils,et al.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.

[453]  A. Klip,et al.  Rab8A and Rab13 are activated by insulin and regulate GLUT4 translocation in muscle cells , 2010, Proceedings of the National Academy of Sciences.

[454]  R. Goody,et al.  The Legionella Effector Protein DrrA AMPylates the Membrane Traffic Regulator Rab1b , 2010, Science.

[455]  D. Lambright,et al.  Rab GEFs and GAPs. , 2010, Current opinion in cell biology.

[456]  Yang Zhang,et al.  Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression. , 2010, Cancer letters.

[457]  Barry S Taylor,et al.  Genomic and biological characterization of exon 4 KRAS mutations in human cancer. , 2010, Cancer research.

[458]  C. Der,et al.  Ras history , 2010, Small GTPases.

[459]  J. Prestegard,et al.  Dynamic structure of membrane-anchored Arf•GTP , 2010, Nature Structural &Molecular Biology.

[460]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[461]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[462]  N. Katsanis,et al.  Bardet-Biedl Syndrome-associated Small GTPase ARL6 (BBS3) Functions at or near the Ciliary Gate and Modulates Wnt Signaling , 2010, The Journal of Biological Chemistry.

[463]  D. Voelker,et al.  Altered lung surfactant system in a Rab38-deficient rat model of Hermansky-Pudlak syndrome. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[464]  I. Just,et al.  Serine‐71 phosphorylation of Rac1/Cdc42 diminishes the pathogenic effect of Clostridium difficile toxin A , 2009, Cellular microbiology.

[465]  M. Ding,et al.  Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. , 2009, Molecular cell.

[466]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[467]  Sandra L. Schmid,et al.  Conserved Functions of Membrane Active GTPases in Coated Vesicle Formation , 2009, Science.

[468]  M. Mann,et al.  Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.

[469]  H. Stenmark.  Rab GTPases as coordinators of vesicle traffic , 2009, Nature Reviews Molecular Cell Biology.

[470]  C. Worby,et al.  The fic domain: regulation of cell signaling by adenylylation. , 2009, Molecular cell.

[471]  Yan Wang,et al.  Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. , 2009, Lung cancer.

[472]  P. Johnston,et al.  RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin , 2008, Oncogene.

[473]  Zhen Lu,et al.  The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. , 2008, The Journal of clinical investigation.

[474]  D. Voelker,et al.  A mutation in Rab38 small GTPase causes abnormal lung surfactant homeostasis and aberrant alveolar structure in mice. , 2008, The American journal of pathology.

[475]  K. Ravichandran,et al.  Phagosome maturation: going through the acid test , 2008, Nature Reviews Molecular Cell Biology.

[476]  Anne J. Ridley,et al.  Mammalian Rho GTPases: new insights into their functions from in vivo studies , 2008, Nature Reviews Molecular Cell Biology.

[477]  E. Hurt,et al.  Membrane curvature induced by Arf1-GTP is essential for vesicle formation , 2008, Proceedings of the National Academy of Sciences.

[478]  Sophie Saunier,et al.  Nephronophthisis , 2008, Pediatric Nephrology.

[479]  A. Ziober,et al.  Activated Vav2 modulates cellular invasion through Rac1 and Cdc42 in oral squamous cell carcinoma. , 2008, Oral oncology.

[480]  S. Nagata,et al.  Imaging of Rab5 activity identifies essential regulators for phagosome maturation , 2008, Nature.

[481]  A. Sweet-Cordero,et al.  Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.

[482]  C. Glembotski,et al.  The role of the unfolded protein response in the heart. , 2008, Journal of molecular and cellular cardiology.

[483]  M. White,et al.  Ral GTPases and cancer: linchpin support of the tumorigenic platform , 2008, Nature Reviews Cancer.

[484]  C. Der,et al.  Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. , 2008, Methods in enzymology.

[485]  C. Der,et al.  Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases* , 2007, Journal of Biological Chemistry.

[486]  David A. Williams,et al.  Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. , 2007, Cancer cell.

[487]  Gideon Bollag,et al.  Biochemical and Functional Characterization of Germ Line KRAS Mutations , 2007, Molecular and Cellular Biology.

[488]  B. Eipper,et al.  Arf6 recruits the Rac GEF Kalirin to the plasma membrane facilitating Rac activation , 2007, BMC Cell Biology.

[489]  Roger L. Williams,et al.  Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS , 2007, The EMBO journal.

[490]  Jacqueline Cherfils,et al.  Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein–protein complexes , 2007, Proceedings of the National Academy of Sciences.

[491]  Dian Donnai,et al.  RAB23 mutations in Carpenter syndrome imply an unexpected role for hedgehog signaling in cranial-suture development and obesity. , 2007, American journal of human genetics.

[492]  Alfred Wittinghofer,et al.  GEFs and GAPs: Critical Elements in the Control of Small G Proteins , 2007, Cell.

[493]  G. Lienhard,et al.  Substrate specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1. , 2007, The Biochemical journal.

[494]  María C Montoya,et al.  MT1‐MMP proinvasive activity is regulated by a novel Rab8‐dependent exocytic pathway , 2007, The EMBO journal.

[495]  M. Stewart.  Molecular mechanism of the nuclear protein import cycle , 2007, Nature Reviews Molecular Cell Biology.

[496]  J. Tcherkezian,et al.  Current knowledge of the large RhoGAP family of proteins , 2007, Biology of the cell.

[497]  Shiro Suetsugu,et al.  The WASP–WAVE protein network: connecting the membrane to the cytoskeleton , 2007, Nature Reviews Molecular Cell Biology.

[498]  D. Nosi,et al.  Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. , 2006, Arthritis and rheumatism.

[499]  G. Raposo,et al.  Rab38 and Rab32 control post-Golgi trafficking of melanogenic enzymes , 2006, The Journal of cell biology.

[500]  P. Hulley,et al.  Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S‐phase arrest, in human myeloma cells , 2006, International journal of cancer.

[501]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[502]  Peter Novick,et al.  Rabs and their effectors: Achieving specificity in membrane traffic , 2006, Proceedings of the National Academy of Sciences.

[503]  D. Boehr,et al.  An NMR perspective on enzyme dynamics. , 2006, Chemical reviews.

[504]  S. Munro,et al.  An N-terminally acetylated Arf-like GTPase is localised to lysosomes and affects their motility , 2006, Journal of Cell Science.

[505]  S. Campbell,et al.  Ras regulation by reactive oxygen and nitrogen species. , 2006, Biochemistry.

[506]  R. Wojcikiewicz,et al.  G-protein-coupled Receptor Agonists Activate Endogenous Phospholipase Cϵ and Phospholipase Cβ3 in a Temporally Distinct Manner* , 2006, Journal of Biological Chemistry.

[507]  T. Stradal,et al.  Protein complexes regulating Arp2/3-mediated actin assembly. , 2006, Current opinion in cell biology.

[508]  Mark Stamnes,et al.  Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro , 2006, Nature chemical biology.

[509]  Jacqueline Cherfils,et al.  RhoGDIs Revisited: Novel Roles in Rho Regulation , 2005, Traffic.

[510]  D. Theodorescu,et al.  RalA and RalB: antagonistic relatives in cancer cell migration. , 2005, Cancer research.

[511]  D. Albertson,et al.  Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2005, Nature.

[512]  A. Mercurio,et al.  Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. , 2005, Cancer research.

[513]  Krister Wennerberg,et al.  The Ras superfamily at a glance , 2005, Journal of Cell Science.

[514]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[515]  P. Vincent,et al.  RhoA and Rho-kinase dependent and independent signals mediate TGF-beta-induced pulmonary endothelial cytoskeletal reorganization and permeability. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[516]  H. Bennett,et al.  A role for the small GTPase Rab21 in the early endocytic pathway , 2004, Journal of Cell Science.

[517]  G. Mills,et al.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.

[518]  Keith A. Boroevich,et al.  Mutations in a member of the Ras superfamily of small GTP-binding proteins causes Bardet-Biedl syndrome , 2004, Nature Genetics.

[519]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[520]  T. Stevens.  Faculty Opinions recommendation of Golgi targeting of ARF-like GTPase Arl3p requires its Nalpha-acetylation and the integral membrane protein Sys1p. , 2004 .

[521]  Yi Zheng,et al.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[522]  Akihiro Kusumi,et al.  Single-molecule imaging analysis of Ras activation in living cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[523]  Rudy Behnia,et al.  Targeting of the Arf-like GTPase Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p , 2004, Nature Cell Biology.

[524]  A. Tong,et al.  Golgi targeting of ARF-like GTPase Arl3p requires its Nα-acetylation and the integral membrane protein Sys1p , 2004, Nature Cell Biology.

[525]  W. J. Wu,et al.  Epidermal Growth Factor-dependent Regulation of Cdc42 Is Mediated by the Src Tyrosine Kinase* , 2003, Journal of Biological Chemistry.

[526]  Yue Zhang,et al.  Regulation of Cell Polarity and Protrusion Formation by Targeting RhoA for Degradation , 2003, Science.

[527]  Jonathan Goldberg,et al.  Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism. , 2003, Molecular cell.

[528]  P. Casey,et al.  High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors* , 2003, Journal of Biological Chemistry.

[529]  J. Donaldson.  Multiple Roles for Arf6: Sorting, Structuring, and Signaling at the Plasma Membrane* , 2003, Journal of Biological Chemistry.

[530]  S. Pfeffer,et al.  Yip3 catalyses the dissociation of endosomal Rab–GDI complexes , 2003, Nature.

[531]  R. Cerione,et al.  Activated Cdc42 Sequesters c-Cbl and Prevents EGF Receptor Degradation , 2003, Cell.

[532]  T. Rabbitts,et al.  Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation , 2003, The EMBO journal.

[533]  A. Hall,et al.  Rho GTPases in cell biology , 2002, Nature.

[534]  Y. Araki,et al.  Di-Ras, a Distinct Subgroup of Ras Family GTPases with Unique Biochemical Properties* , 2002, The Journal of Biological Chemistry.

[535]  R. A. Corpina,et al.  Structure of the Sec23/24–Sar1 pre-budding complex of the COPII vesicle coat , 2002, Nature.

[536]  John D. Scott,et al.  Rab32 is an A-kinase anchoring protein and participates in mitochondrial dynamics , 2002, The Journal of cell biology.

[537]  Alexandre V. Podtelejnikov,et al.  Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck , 2002, Nature.

[538]  K. Weis.  Nucleocytoplasmic transport: cargo trafficking across the border. , 2002, Current opinion in cell biology.

[539]  Makoto Fukuda,et al.  The GTPase Ran Regulates Chromosome Positioning and Nuclear Envelope Assembly In Vivo , 2002, Current Biology.

[540]  E. Sahai,et al.  RHO–GTPases and cancer , 2002, Nature Reviews Cancer.

[541]  D. Whyte,et al.  Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines* , 2002, The Journal of Biological Chemistry.

[542]  Long Yu,et al.  Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. , 2002, Gene expression.

[543]  T. Balla,et al.  Phosphatidylinositol 4,5-bisphosphate and Arf6-regulated membrane traffic , 2001, The Journal of cell biology.

[544]  J. Freed,et al.  ADP ribosylation factor 6 binding to phosphatidylinositol 4,5-bisphosphate-containing vesicles creates defects in the bilayer structure: an electron spin resonance study. , 2001, Biophysical journal.

[545]  I R Vetter,et al.  Dynamic properties of the Ras switch I region and its importance for binding to effectors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[546]  Iain W. Mattaj,et al.  Ran–GTP coordinates regulation of microtubule nucleation and dynamics during mitotic-spindle assembly , 2001, Nature Cell Biology.

[547]  A. Smrcka,et al.  Phospholipase Cϵ: a novel Ras effector , 2001 .

[548]  E. Sahai,et al.  Cross‐talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility , 2001, The EMBO journal.

[549]  A. Smrcka,et al.  Phospholipase C(epsilon): a novel Ras effector. , 2001, The EMBO journal.

[550]  Kenneth M. Yamada,et al.  Dual Stimulation of Ras/Mitogen-Activated Protein Kinase and Rhoa by Cell Adhesion to Fibronectin Supports Growth Factor–Stimulated Cell Cycle Progression , 2000, The Journal of cell biology.

[551]  R. Fucini,et al.  Activated ADP-ribosylation Factor Assembles Distinct Pools of Actin on Golgi Membranes* , 2000, The Journal of Biological Chemistry.

[552]  A. Hall,et al.  Rho GTPases and their effector proteins. , 2000, The Biochemical journal.

[553]  A. Fischer,et al.  Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome , 2000, Nature Genetics.

[554]  Nicholas J. Cowan,et al.  Adp Ribosylation Factor-like Protein 2 (Arl2) Regulates the Interaction of Tubulin-Folding Cofactor D with Native Tubulin , 2000, The Journal of cell biology.

[555]  P. Clarke,et al.  Chromatin-independent nuclear envelope assembly induced by Ran GTPase in Xenopus egg extracts. , 2000, Science.

[556]  G L Johnson,et al.  Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[557]  R. Scheller,et al.  Rab37 is a novel mast cell specific GTPase localized to secretory granules , 2000, FEBS letters.

[558]  Jaesun Chun,et al.  Akt Protein Kinase Inhibits Rac1-GTP Binding through Phosphorylation at Serine 71 of Rac1* , 2000, The Journal of Biological Chemistry.

[559]  G. Rodan,et al.  Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. , 2000, Archives of biochemistry and biophysics.

[560]  D. Alessi,et al.  Evidence That 3-Phosphoinositide-dependent Protein Kinase-1 Mediates Phosphorylation of p70 S6 Kinase in Vivoat Thr-412 as well as Thr-252* , 1999, The Journal of Biological Chemistry.

[561]  M. Frohman,et al.  Phosphatidylinositol 4-Phosphate 5-Kinase a Is a Downstream Effector of the Small G Protein ARF 6 in Membrane Ruffle Formation 1984 , 1999 .

[562]  E. Pieterman,et al.  Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. , 1999, Biochemical and biophysical research communications.

[563]  T. Morimoto,et al.  Endomembrane Trafficking of Ras The CAAX Motif Targets Proteins to the ER and Golgi , 1999, Cell.

[564]  M. Dasso,et al.  The Ran GTPase regulates mitotic spindle assembly , 1999, Current Biology.

[565]  M. Kirschner,et al.  The Interaction between N-WASP and the Arp2/3 Complex Links Cdc42-Dependent Signals to Actin Assembly , 1999, Cell.

[566]  R. Schekman,et al.  A Primer on Vesicle Budding , 1999, Cell.

[567]  Frank McCormick,et al.  Brefeldin A The Advantage of Being Uncompetitive , 1999, Cell.

[568]  Shiro Suetsugu,et al.  WAVE, a novel WASP‐family protein involved in actin reorganization induced by Rac , 1998, The EMBO journal.

[569]  J. Brown,et al.  Interaction of a novel GDP exchange inhibitor with the Ras protein. , 1998, Biochemistry.

[570]  C. Marshall,et al.  Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1 , 1998, Nature.

[571]  S. Michaelis,et al.  Mammalian Prenylcysteine Carboxyl Methyltransferase Is in the Endoplasmic Reticulum* , 1998, The Journal of Biological Chemistry.

[572]  T. Kataoka,et al.  Identification of PLC210, a Caenorhabditis elegansPhospholipase C, as a Putative Effector of Ras* , 1998, The Journal of Biological Chemistry.

[573]  I. Mattaj,et al.  Nucleocytoplasmic transport: the soluble phase. , 1998, Annual review of biochemistry.

[574]  F. McCormick,et al.  Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation , 1997, Molecular and cellular biology.

[575]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[576]  M. Lewis,et al.  Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo * , 1997, The Journal of Biological Chemistry.

[577]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[578]  L. Perkins,et al.  Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. , 1997, Bioorganic & medicinal chemistry.

[579]  Yoshiharu Matsuura,et al.  Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase)* , 1996, The Journal of Biological Chemistry.

[580]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[581]  P. D’Eustachio,et al.  The small nuclear GTPase Ran: How much does it run? , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[582]  D. Noh,et al.  Phosphoinositide-specific phospholipase C and mitogenic signaling. , 1995, Biochimica et biophysica acta.

[583]  F. McCormick,et al.  A role for Rho in Ras transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[584]  F. McCormick,et al.  An essential role for Rac in Ras transformation , 1995, Nature.

[585]  J. Goldstein,et al.  Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*) , 1995, The Journal of Biological Chemistry.

[586]  I. Schlichting,et al.  Substrate and product structural requirements for binding of nucleotides to H-ras p21: the mechanism of discrimination between guanosine and adenosine nucleotides. , 1995, Biochemistry.

[587]  M. Cobb,et al.  Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells. , 1994, The Journal of biological chemistry.

[588]  M. Wigler,et al.  Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. , 1993, Science.

[589]  P. Sluijs,et al.  Reversible phosphorylation‐‐dephosphorylation determines the localization of rab4 during the cell cycle. , 1992, The EMBO journal.

[590]  H. Kole,et al.  Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts. , 1991, Archives of biochemistry and biophysics.

[591]  M. Bornens,et al.  Phosphorylation of two small GTP-binding proteins of the Rab family by p34cdc2 , 1991, Nature.

[592]  U. Banerjee,et al.  Genetic dissection of a neurodevelopmental pathway: Son of sevenless functions downstream of the sevenless and EGF receptor tyrosine kinases , 1991, Cell.

[593]  P. Casey,et al.  Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. , 1991, Cell.

[594]  Margaret Robertson,et al.  The neurofibromatosis type 1 gene encodes a protein related to GAP , 1990, Cell.

[595]  M. Zerial,et al.  Localization of low molecular weight GTP binding proteins to exocytic and endocytic compartments , 1990, Cell.

[596]  J. Lippincott-Schwartz,et al.  Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin a suggests an ER recycling pathway , 1990, Cell.

[597]  P. Casey,et al.  p21ras is modified by a farnesyl isoprenoid. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[598]  Michael J. Berridge,et al.  Inositol phosphates and cell signalling , 1989, Nature.

[599]  A. Chobanian,et al.  Regulation of intracellular calcium by cell pH in vascular smooth muscle cells. , 1989, The American journal of physiology.

[600]  S H Kim,et al.  Three-dimensional structure of an oncogene protein: catalytic domain of human c-H-ras p21. , 1988, Science.

[601]  F. McCormick,et al.  A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. , 1987, Science.

[602]  E. Racker,et al.  Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.